Remdesivir

Background

Remdesivir, an antiviral originally developed for Ebola and subsequently repurposed for COVID-19, is being investigated for its potential to treat long COVID. It works by inhibiting viral RNA polymerase, preventing SARS-CoV-2 from replicating effectively. Remdesivir may help in cases where viral persistence is suspected.

Mechanism of Action

• Remdesivir: Inhibits RNA-dependent RNA polymerase (RdRp), which SARS-CoV-2 requires for replication. This inhibition stops the virus from replicating, potentially reducing viral load in patients with persistent infection (Remdesivir Study).

Pros and Cons

• Pros: Directly targets viral replication; intravenous administration may increase effectiveness in clinical settings.
• Cons: Requires IV administration, limiting accessibility; possible side effects include kidney and liver function impacts, necessitating monitoring.

References

1. Remdesivir Study

‍